title: Effect of intraperitoneal injection of sulodexide on peritoneal function and albumin leakage in continuous ambulatory peritoneal dialysis patients.
abstract: Peritoneal protein loss is one of the inevitable consequences during continuous ambulatory peritoneal dialysis (CAPD). Our objective was to study the effect of sulodexide on the protein loss and efficiency of dialysis. This study included six patients receiving CAPD treated with sulodexide at the dose of 600 IU/day given by intraperitoneal injection for 10 days. Clinical and biologic parameters were assessed before starting the treatment (D0 and after 10 days of treatment (D10. We also evaluated the benefit of therapy persisting 20 days after the end of treatment (D30. The sulodexide administration produced a significant improvement of the peritoneal function as determined by a significant increase in the following ratios measured at the 4 th h of dwell time on D0 and D30: dialysate-to plasma (D/P) creatinine from 0.63 ± 1.45 to 0.85 ± 0.073 (P = 0.028) and D/P urea from 0.63 ± 0.15 to 79 ± 0.2 (P = 0.048). A significant decrease of albumin leakage was observed, which was 0.90 ± 0.40 g/L at baseline, 0.67 ± 0.36 g/L on the 10 th day, and 0.43 ± 0.22g/L 20 days after the end of treatment. Within 10-day treatment period, use of sulodexide resulted in a reduction in the peritoneal loss of albumin, in addition to improvement of the quality of dialysis and the residual renal function among these patients.
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Yosra
authors.initials: Y
authors.lastname: Guedri
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: K Najla
authors.initials: KN
authors.lastname: Damma
authors.affiliation: Faculty of Pharmacy, Monastir, Tunisia.
authors.forename: Melek
authors.initials: M
authors.lastname: Toumi
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Wissal
authors.initials: W
authors.lastname: Sahtout
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Awatef
authors.initials: A
authors.lastname: Azzabi
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Sinda
authors.initials: S
authors.lastname: Mrabet
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Safa
authors.initials: S
authors.lastname: Nouira
authors.affiliation: Faculty of Pharmacy, Monastir, Tunisia.
authors.forename: Dalila
authors.initials: D
authors.lastname: Saidane
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Samira
authors.initials: S
authors.lastname: Amor
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Anis
authors.initials: A
authors.lastname: Belarbia
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Dorsaf
authors.initials: D
authors.lastname: Zellama
authors.affiliation: Department of Nephrology, Dialysis and Transplantation, Sahloul Hospital, Sousse, Tunisia.
authors.forename: Abdellatif
authors.initials: A
authors.lastname: Achour
mesh_terms: D000418:Albumins; D015314:Dialysis Solutions; D006025:Glycosaminoglycans; D006801:Humans; D007274:Injections, Intraperitoneal; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum; D006435:Renal Dialysis
chemical_list: D000418:Albumins; D015314:Dialysis Solutions; D006025:Glycosaminoglycans; C007858:glucuronyl glucosamine glycan sulfate